|

Asciminib Pediatric formulation Clinical Trials

1 actively recruiting trial

Also known as: ABL001

Pipeline

Phase 1/2: 1

Top Sponsors

  • Novartis Pharmaceuticals1

Indications

  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia1
  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1
  • Acute Lymphoblastic Leukemia1
  • Cancer1

Other1 trial

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.